Revenue
24.2 thousand USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 24245 USD Source
Fundies. English
JUPITER NEUROSCIENCES, INC.
EDGARAnnual consolidated revenue for 2025: about USD 21.8K, using the latest reported figures.
Latest quarter
Operating margin
-11,313.45%
2026 Q2 · %
Operating cash flow
-2.29 million USD
2026 Q2 · USD
- Cash and cash equivalents
- Not available
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 665 thousand shares Source
Exact value
664670 shares
Reported share-count change
-98.09% · -34.2 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-9.2 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Operating cash flow
-7.25 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -3045713 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -1891263 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -5413736 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -3045713 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -1432100 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -3727022 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -1432100 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-09-25.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2025-12-31
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 1 of 11 periods available· newest 2025-12-31
- Total liabilities: 1 of 11 periods available· newest 2025-12-31
- Current assets: 1 of 11 periods available· newest 2025-12-31
- Current liabilities: 1 of 11 periods available· newest 2025-12-31
- cash and cash equivalents: No compatible figures in this window
- long term debt: No compatible figures in this window
- Shares outstanding: 1 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 6.21 millionPrior period
−USD 2.44 million
–
Current period
−USD 8.64 million
–
Exact inputs and evidence
-8644897 − -2439625 = -6205272 USD
-2439625 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-8644897 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.5 millionPrior period
−USD 3.91 million
–
Current period
−USD 5.41 million
–
Exact inputs and evidence
-5413736 − -3911004 = -1502732 USD
-3911004 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-5413736 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 21,796 100% of revenue
- Cost of revenue USD 4,231 19% of revenue
- Operating expenses USD 8.93 million 40,954% of revenue
- Operating income −USD 8.91 million −40,873% of revenue
- Tax, interest and other Derived −USD 263,824 −1,210% of revenue
- Net income −USD 8.64 million −39,663% of revenue
Cash
- Operating cash flow −USD 5.41 million −24,838% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2025 Operating loss: operating costs were 40,973% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2025 2025-01-01 – 2025-12-31 | 21796 | 8930517 Derived | -8908721 | -263824 Derived | -8644897 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 21.8K 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Revenue | 21796 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -40,873.2% 2025
Net margin -39,662.8% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Operating margin | -40,873.2% |
|
| 2025 | Net margin | -39,662.8% |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -5.4M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Operating cash flow | -5413736 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
132.9% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Liabilities / assets | 132.9% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
0.65× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2025 | Current assets / current liabilities | 0.65× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 4.78 million Exact valueExact value: -4783689 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 480,953 Exact valueExact value: -480953 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 2.44 million Exact valueExact value: -2439625 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.91 million Exact valueExact value: -3911004 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 8.64 million Exact valueExact value: -8644897 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.41 million Exact valueExact value: -5413736 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
16 filings · 511 latest values · 511 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001679628, 1679628, JUNS, edgar:1679628
Also known as JUPITER NEUROSCIENCES, INC., Jupiter Neurosciences, Inc., Jupiter Orphan Therapeutics, Inc.